KLRS
Income statement / Annual
Last year (2025), Kalaris Therapeutics Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Kalaris Therapeutics Inc.'s net income was -$43.44 M.
See Kalaris Therapeutics Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$165.00 K |
$1.14 M |
| Cost of Revenue |
$13.00 K
|
$0.00
|
$0.00
|
$0.00
|
$1.12 M
|
$73.00 K
|
$0.00
|
$0.00
|
| Gross Profit |
-$13.00 K
|
$0.00
|
$0.00
|
$0.00
|
-$1.12 M
|
-$73.00 K
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$30.75 M
|
$12.34 M
|
$11.71 M
|
$11.76 M
|
$119.62 M
|
$49.59 M
|
$16.23 M
|
$1.70 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$1.76 M
|
$2.24 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$15.39 M
|
$42.92 M
|
$1.76 M
|
$2.24 M
|
$49.08 M
|
$21.65 M
|
$10.62 M
|
$3.03 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$46.14 M
|
$55.26 M
|
$13.46 M
|
$14.01 M
|
$168.70 M
|
$71.24 M
|
$26.85 M
|
$4.73 M
|
| Cost And Expenses |
$46.15 M
|
$55.26 M
|
$13.46 M
|
$14.01 M
|
$169.82 M
|
$71.31 M
|
$26.87 M
|
$4.73 M
|
| Interest Income |
$0.00
|
$5.49 M
|
$0.00
|
$0.00
|
$1.32 M
|
$1.33 M
|
$2.07 M
|
$56.00 K
|
| Interest Expense |
$1.44 M
|
$0.00
|
$687.00 K
|
$235.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$13.00 K
|
$0.00
|
$0.00
|
$0.00
|
$1.12 M
|
$73.00 K
|
$19.00 K
|
$0.00
|
| EBITDA |
-$41.98 M |
-$58.77 M |
-$14.01 M |
-$15.25 M |
-$169.84 M |
-$69.71 M |
-$23.82 M |
-$2.43 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
-144.36
|
-2.14
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
-161.82
|
-3.17
|
| Total Other Income/Expenses Net |
$2.71 M
|
-$3.51 M
|
-$1.24 M
|
-$1.48 M
|
-$1.14 M
|
$1.53 M
|
$2.86 M
|
$1.17 M
|
| Income Before Tax |
-$43.44 M
|
-$58.77 M
|
-$14.70 M
|
-$15.49 M
|
-$170.96 M
|
-$69.78 M
|
-$23.84 M
|
-$2.43 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
-144.48
|
-2.14
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.01 M
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$43.44 M
|
-$58.77 M
|
-$14.70 M
|
-$15.49 M
|
-$171.96 M
|
-$69.78 M
|
-$23.84 M
|
-$2.43 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
-144.48
|
-2.14
|
| EPS |
-2.85 |
-11.73 |
-42.0886 |
-50.6207 |
-63 |
-59.67 |
-8.42 |
-2.88 |
| EPS Diluted |
-2.85 |
-11.73 |
-42.0886 |
-50.6207 |
-63 |
-59.67 |
-8.42 |
-2.88 |
| Weighted Average Shares Out |
$15.27 M
|
$5.01 M
|
$4.52 M
|
$3.33 M
|
$2.73 M
|
$1.17 M
|
$2.83 M
|
$2.83 M
|
| Weighted Average Shares Out Diluted |
$15.27 M
|
$5.01 M
|
$4.52 M
|
$3.33 M
|
$2.73 M
|
$1.17 M
|
$2.83 M
|
$2.83 M
|
| Link |
|
|
|
|
|
|
|
|
